Literature DB >> 11555622

Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes.

K Lieuallen1, L A Pennacchio, M Park, R M Myers, G G Lennon.   

Abstract

Loss-of-function mutations in the cystatin B (Cstb) gene cause a neurological disorder known as Unverricht-Lundborg disease (EPM1) in human patients. Mice that lack Cstb provide a mammalian model for EPM1 by displaying progressive ataxia and myoclonic seizures. We analyzed RNAs from brains of Cstb-deficient mice by using modified differential display, oligonucleotide microarray hybridization and quantitative reverse transcriptase polymerase chain reaction to examine the molecular consequences of the lack of Cstb. We identified seven genes that have consistently increased transcript levels in neurological tissues from the knockout mice. These genes are cathepsin S, C1q B-chain of complement (C1qB), beta2-microglobulin, glial fibrillary acidic protein (Gfap), apolipoprotein D, fibronectin 1 and metallothionein II, which are expected to be involved in increased proteolysis, apoptosis and glial activation. The molecular changes in Cstb-deficient mice are consistent with the pathology found in the mouse model and may provide clues towards the identification of therapeutic points of intervention for EPM1 patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555622     DOI: 10.1093/hmg/10.18.1867

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  26 in total

1.  Differences in aggregation properties of three site-specific mutants of recombinant human stefin B.

Authors:  Manca Kenig; Selma Berbić; Aida Krijestorac; Louise Kroon-Zitko; Magda Tusek; Marusa Pompe-Novak; Eva Zerovnik
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

2.  Role of cystatin C in neuroprotection and its therapeutic implications.

Authors:  Luciano D'Adamio
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

3.  Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

Authors:  Dun-Sheng Yang; Philip Stavrides; Panaiyur S Mohan; Susmita Kaushik; Asok Kumar; Masuo Ohno; Stephen D Schmidt; Daniel Wesson; Urmi Bandyopadhyay; Ying Jiang; Monika Pawlik; Corrinne M Peterhoff; Austin J Yang; Donald A Wilson; Peter St George-Hyslop; David Westaway; Paul M Mathews; Efrat Levy; Ana M Cuervo; Ralph A Nixon
Journal:  Brain       Date:  2011-01       Impact factor: 13.501

4.  In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1.

Authors:  Sabina Rabzelj; Vito Turk; Eva Zerovnik
Journal:  Protein Sci       Date:  2005-09-09       Impact factor: 6.725

Review 5.  Neuronal survival in epilepsy: to die or not to die?

Authors:  Subramaniam Ganesh; Shweta Singh
Journal:  J Biosci       Date:  2005-12       Impact factor: 1.826

6.  Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells.

Authors:  Nagathihalli S Nagaraj; Nadarajah Vigneswaran; Wolfgang Zacharias
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-16       Impact factor: 4.553

7.  Plasma Cystatin B Association With Abdominal Aortic Aneurysms and Need for Later Surgical Repair: A Sub-study of the VIVA Trial.

Authors:  Yunzhe Wang; Cong-Lin Liu; Jes S Lindholt; Guo-Ping Shi; Jinying Zhang
Journal:  Eur J Vasc Endovasc Surg       Date:  2018-09-24       Impact factor: 7.069

8.  Transcriptomic analysis in the leech Theromyzon tessulatum: involvement of cystatin B in innate immunity.

Authors:  Christophe Lefebvre; Claude Cocquerelle; Franck Vandenbulcke; David Hot; Ludovic Huot; Yves Lemoine; Michel Salzet
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

9.  Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes.

Authors:  B Bindukumar; S D Mahajan; J L Reynolds; Z Hu; D E Sykes; R Aalinkeel; S A Schwartz
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

10.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis.

Authors:  Remington L Nevin
Journal:  Malar J       Date:  2009-08-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.